Monograph

C09AA05 - Ramipril

Propably not porphyrinogenic

Rationale

No data pointing to CYP-interactions. One reference stating probable non-porphyrinogenicity. Risk for gastrointestinal adverse events in the form of digestive disturbances, dyspepsia, diarrhoea, nausea and vomiting motivates vigilance against insufficient intake of food, especially of carbohydrate.

Chemical description

Alanine derivative which is hydrolyzed in the liver giving rise to the ACE- inhibitor ramiprilate. Also other metabolites are produced. No data pointing to CYP-interactions. South African list: use with care.

Therapeutic characteristics

Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are abdominal pain, dyspepsia, diarrhoea, nausea and vomiting. Other common side effects are muscle spasms, myalgia, headache and fatigue.

IPNet drug reports

Uneventful use reported in 29 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes C09A / C09AA or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames